BCG-unresponsive NMIBC trials feel confusing—and inconsistent EFS reporting is a big reason why We analyze the CIS+ cohorts of 4-FDA registration trials to provide interpretable EFS estimates 🧵👇 @Annals_Oncology @tompowles1 @JoshMeeks @wandering_gu https://t.co/UVlffMc8qY

“Low-grade Non–Muscle-Invasive Bladder Cancer: Molecular Landscape, Treatment Strategies, and Emerging Therapies” - just published in Nature Reviews Urology @NatRevUrol.  This State-of-the-Art review by Drs. Roger Li @UrogerliMD, Lexi Wen, and colleagues @philippespiess

Great brainstorming session today at #EMUC25 focused on advancing the most current insights in urothelial carcinoma research 🚀

One slide says it all! Terrific distillation by @MichvdHeijden of what to do in emerging pt populations in #bladdercancer, namely pts who received perioperative IO. Mirrors discussions we have been having in #kidneycancer. #ESMO25

⚡️ Cost-effectiveness of treatments for BCG-unresponsive CIS - analysis from our multicenter IBCG team. Five strategies modeled: 🔹Radical cystectomy (RC) 🔹Pembrolizumab 🔹Nadofaragene firadenovec 🔹Nogapendekin (NAI-BCG) 🔹Gemcitabine + Docetaxel ➡️Comprehensive

In a trial of men with suspected prostate cancer, biparametric MRI, which excludes the gadolinium contrast sequence, was noninferior to multiparametric MRI for detecting clinically significant cases. 🧵 https://t.co/t4f6t0k1uF

On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with BCG - unresponsive NMIBC with CIS with or without papillary tumors. Also known as TAR-200: this gemcitabine intravesical system is

JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! @NateraGenetics @tompowles1 @Roche https://t.co/OlOirNfWHo

The Prostate Imaging for Recurrence Reporting (PI-RR) system standardizes MRI performance and interpretation after prostatectomy or radiation therapy and is an essential reference for radiologists in standardizing reporting of recurrent prostate cancer. https://t.co/8rLeQSVn2x

Confirmation of the results of our RCT showing that PLND reduces metastasis without affecting BCR. @UrologyMSK @Uroweb @EUplatinum @JUrology @VickersBiostats #prostatecancer

Our team is in Sevilla for #UROonco25 📩 #NMIBC Deintensify LG Biomarkers to ⬇️ cystoscopy in HG #MIBC ctDNA is the future #UTUC Tailored patient care Go for kidney-sparing treatment @Uroweb @EAU_Uroonco @EAUYAUrology

Excellent comprehensive review + metaanalysis on the diagnostic role of #PSMA Pet in #ProstateCancer ✅ High diagnostic value of PSMA PET, especially when combined with #MRI ✅ NPV indicates limitations to guide LND - not enough to omit biopsy @EUplatinum @oncodaily @elio_mazzone

A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol https://t.co/trmFp9Yd0y There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

NEW: The EAU Guidelines Bot The right answers, seconds away Ask personalised treatment questions and receive instant answers based on the EAU Guidelines. Available in each topic section of the EAU Guidelines. Try it today via the Guidelines page: https://t.co/SmUgAEcPnQ

Great talks and state of the art lectures here in Palermo about novel evidence among all Uro-Oncology fields. Glad to discuss clinical case scenario in MIBC on TMT vs. radical cystectomy. Congrats to @Nicp85Pavan and all the Scientific Committee for this excellent meeting 🚀

DOMANI 10 e 11 aprile a Castelfranco Veneto 📆 🩺 Advanced Uro-Oncology Days - 3° Edizione Due giornate dedicate all’evoluzione delle terapie nelle neoplasie urologiche, con focus su approcci multidisciplinari, integrazione di nuove molecole e applicazione pratica delle più

NMIBC trial timelines: <2020 to 2028+ Unbelievable disease space at the moment! @tbivala1 @urotoday #EAU25

Proud to stand alongside this incredible group of innovators and leaders in urology. The future of our field is in great hands. #Urology #EAU2025

Mistakes happen! 🔄 After correcting the results, we found: 📌 1817 lesions – 1529 MRI – 1325 patients 📍 Mapped Transperineal Biopsies 🔹 MRI-: 8% CsPCa 🔸 PIRADS 3: 25% CsPCa 🔺 PIRADS 4-5: 68% CsPCa https://t.co/Yv2xikIyxA

Honored to join the @EAU_YAUrotheli as an Associate Member! Very grateful to @UroMoschini and @GiorgioI_Russo for this unique opportunity and to all my mentors that supported me in these years 🙏🏻 Looking forward to collaborating with this incredible team 🚀